Skip to main content
Loading...

About Us

Get to know CARBOGEN AMCIS

Who we are

Welcome to CARBOGEN AMCIS, a member of the Dishman Carbogen Amcis Group. We provide drug development and commercialisation services to the pharmaceutical and biopharmaceutical industries, at all stages of drug development. Our capabilities span from contract chemical process research and development to the supply of Active Pharmaceutical Ingredients (APIs) - as well as drug products for preclinical studies, clinical trials and commercial use. Besides being a service provider we also offer high quality Cholesterol and Vitamin D analog products produced at our facility in The Netherlands. These products are used in a variety of markets around the globe.

Our focus is to help customers create a better world by becoming the partner of choice for development and manufacture. The guiding principles for our service are our passion for great science supported by timely communication and backed by our total commitment to YOUR project.

We forge close collaboration and open communication with our customers which ensures we work effectively as a team, meeting (if not exceeding) our customers' expectations. We aim to manufacture pharmaceutical ingredients at the highest standard of GMP whilst protecting the environment.

We are a partner you can trust and we look forward to helping you move your project faster to the market!

Our vision

We bring science to life by providing innovative solutions in products and services, contributing to the well-being of people and the planet.

Our mission

We apply our experience and outstanding quality in the provision of exceptional chemical process development, manufacturing & formulation services and products for our customers . We focus on high efficiency , reliability and finding innovative, safe, economically and environmentally optimal solutions.

Our vision & mission

Company history

With over 30 years’ experience, we have supported the pharmaceutical and biopharmaceutical industries with drug development and bringing new drugs to market to improve human health.

CARBOGEN AMCIS was born out of CarboGen, founded in 1990 at the University of Zurich and also AMCIS which was founded in 1982. The companies were both acquired by Solutia in 2000 and merged into the single legal entity now known as CARBOGEN AMCIS AG. Since then, we have continued to grow organically, and employ more than 600 people.

In August 2006, CARBOGEN AMCIS AG was acquired by Dishman Carbogen Amcis Ltd. (previously known as Dishman Pharmaceuticals and Chemicals Limited,) – allowing us within the Dishman Carbogen Amcis group to provide our customers with a fully flexible and effective customised delivery strategy for the entire life of a compound. This partnership has enabled CARBOGEN AMCIS to maintain its position as an industry leader and outsourcing partner for complex highly potent APIs and ADCs.

Foundation of AMCIS (Bubendorf) as joint venture with a pharmaceutical company in USA
1982

Foundation Dishman Pharmaceutical and Chemicals Ltd
1983

First Quats production facility established in Naroda
1989

Foundation CarboGen (Aarau) as Spin-off of the University of Zurich focused and early-phase API supply
1990

First production facility for bulk intermediates and API established in Bavla
1996

Creation of Dishman Europe and Dishman USA subsidiaries
1998

Acquisition of CarboGen and AMCIS by Solutia
2000

Acquisition of the Manchester site
2003

Creation of CARBOGEN AMCIS AG and acquisition by Dishman Pharmaceuticals and Chemicals Ltd
2006

Formation of Dishman Japan and Dishman China. Acquisition of Dishman Netherlands
2007

Integration of the Manchester site into CARBOGEN AMCIS
2007

Acquisition of Riom (France) site CARBOGEN AMCIS SAS
2012

Established Dishman Care
2014

Acquisition of the Vionnaz (CH) site CARBOGEN AMCIS
2014

Integration of the Shanghai site into CARBOGEN AMCIS
2015

Company name changed to Dishman Carbogen Amcis Limited
2017

Integration of the Veenendaal site into CARBOGEN AMCIS
2018

Opening of a new site dedicated to the production of liquid and lyophilised sterile drug products, in Saint-Beauzire (France)
2023

Our locations


Board of Directors

Christian Eich

Chairman + General Legal Counsel

Pascal Villemagne

Delegate + Chief Executive Officer (CEO)

Stephan Fritschi, Ph.D.

Delegate

Arpit Vyas

Member

Harshil Dalal

Member

Ashok Gandhi

Member

Ariane Gschwind

Secretary (not being a member)

Executive Board Members

Arpit Vyas

Managing Director

Pascal Villemagne

Chief Executive Officer (CEO)

Stephan Fritschi

Chief Alliance Officer

Harshil Global

Chief Financial Officer (CFO)

Global Corporate Office

Harshil Dalal

Chief Financial Officer (CFO)

François Baduel

Chief Business Officer (CBO)

Martin Schneider

Chief Compliance Officer (CCO)

Alan Fischer

Chief Technology Officer (CTO)

Sabrina Peinal

Vice President Human Resources

Business Units

Angie Stevens

Vice President Business Unit Drug Product

Carl Baker

Vice President Business Unit Drug Substance

Gerard Faaij

Vice President Business Unit Specialities